In simple terms, RegeneRx Biopharmaceuticals, Inc. has 149.697 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -17.757%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -24.089%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -9.898% return, is a testament to RegeneRx Biopharmaceuticals, Inc.'s adeptness in optimizing resource deployment. RegeneRx Biopharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.561%. Furthermore, the proficiency of RegeneRx Biopharmaceuticals, Inc. in capital utilization is underscored by a remarkable 0.845% return on capital employed.
Stock Prices
RegeneRx Biopharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.03, while its low point bottomed out at $0.01. This variance in figures offers investors a lucid insight into the roller-coaster ride that is RegeneRx Biopharmaceuticals, Inc.'s stock market.
Company general description and statistics
Sector: Healthcare
Industry: Biotechnology
CEO:Mr. J. J. Finkelstein
Full-time employees:2
City:Rockville
Address:15245 Shady Grove Road
IPO:2003-10-07
CIK:0000707511
Website:
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
